Changes in exercise endurance and inspiratory capacity after lumacaftor/ivacaftor therapy in cystic fibrosis
Saved in:
| Main Authors: | D. Savi, A. Gramegna, M. Vicenzi, M. Di Paolo, B. Messore, P. Palange, F. Blasi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis
2023-07-01
|
| Series: | Pulmonology |
| Online Access: | https://www.tandfonline.com/doi/10.1016/j.pulmoe.2022.09.009 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation
by: Steven J Edwards, et al.
Published: (2025-05-01) -
Clinical Efficacy and Safety of Ivacaftor/Lumacaftor Combination in Patients with Cystic Fibrosis: International Studies Review
by: Nataliya Yu. Kashirskaya, et al.
Published: (2021-12-01) -
Evaluation of the Effectiveness of Using the CFTR Modulator Ivacaftor/Lumacaftor in Children with Cystic Fibrosis in the Sverdlovsk Region (Prospective Cohort Study)
by: Yuliya O. Vasenyova, et al.
Published: (2024-09-01) -
Analysis of Ivacaftor drug approval for cystic fibrosis patients with gating mutations.
by: Nemirajaiah, S.
Published: (2021-08-01) -
A real-life study of elexacaftor-tezacaftor-ivacaftor therapy in people with cystic fibrosis in Brazil
by: L.Z. Salomão, et al.
Published: (2023-11-01)